Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01605435 · ClinicalTrials.gov registry record · Phase 2
Ghrelin Dose Finding In Frail Elderly
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01605435: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT01605435 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01605435, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Frailty is a geriatric syndrome leading to physical deterioration including muscle wasting (sarcopenia) and unintentional weight loss. There are currently no approved therapies for frailty. Ghrelin is a hormone produced by the stomach that stimulates appetite centers in the brain. The purpose of this study is to determine the optimal subcutaneous ghrelin dose as a potential intervention for frail elderly individuals. We will examine food intake and metabolic parameters after placebo and ghrelin administration at three escalating subcutaneously administered doses.
Interventions
- DRUG Ghrelin Group 1
- DRUG Ghrelin Group 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-05 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01605435
The ClinicalTrials.gov registry entry for NCT01605435 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ghrelin Group 1 is the first listed.
NCT01605435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01605435 about?
NCT01605435 is a clinical study titled "Ghrelin Dose Finding In Frail Elderly". Frailty is a geriatric syndrome leading to physical deterioration including muscle wasting (sarcopenia) and unintentional weight loss. There are currently no approved therapies for frailty. Ghrelin is a hormone produced by the stomach that stimulates appetite centers in the brain. The purpose of thi...
What is the current status of trial NCT01605435?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2012-05. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01605435?
The interventions under investigation include: Ghrelin Group 1 (DRUG), Ghrelin Group 2 (DRUG).
Who is sponsoring clinical trial NCT01605435?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.